Scholarlink

Purpose <p>To investigate the therapeutic effects of puerarin in reducing adipogenesis and controlling inflammation in primary orbital fibroblasts derived from patients with thyroid eye disease (TED), and to explore the potential underlying mechanisms.</p> Methods <p>After primary fibroblast culture and identification, the Cell Counting Kit-8 (CCK-8) was used to estimate the cytotoxic effects of puerarin. Wound-healing test was performed to assess the impact of puerarin on cellular migration. Adipogenic models were built with or without puerarin and inflammation model was built with the induction of IL-1β. Levels of IL-6, IL-8, CXCL-1, ADIPOQ, FABP4, and PPARγ were determined using quantitative real-time polymerase chain reaction (PCR). IL-6 and IL-8 in the cell supernatant were measured using enzyme-linked immunosorbent assay (ELISA). We performed network pharmacology and molecular docking to identify possible pathway and validated with Western blot.</p> Results <p>Puerarin significantly reduce the wound healing area and lipid area (<i>p</i> &lt; 0.001, <i>p</i> = 0.004, <i>p</i> &lt; 0.001 for 5µM, 10µM and 25µM, respectively) but no difference was found between the different puerarin groups. The levels of ADIPOQ, FABP4, and PPARγ were significantly decreased in the 5µM-puerarin treated group (<i>p</i> = 0.032, 0.041, 0.008, respectively), and the levels of IL-6 and IL-8 were significantly decreased in the puerarin-treated inflammation group (<i>p</i> &lt; 0.01). PIK3CA and AKT 1 were identified as core targets, and the results were further supported by western blotting.</p> Conclusion <p>Puerarin has anti-adipogenic and anti-inflammatory effects on the fibroblasts of patients with TED. These effects may be mediated by the PI3K-AKT pathway. Puerarin may be a potential treatment option for TED.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Puerarin suppress adipogenesis and inflammation on orbital fibroblasts from patients with thyroid eye disease

  • 期刊论文

  • 发表日期：

    2025年11月10日

查看全文
  • Lan Ma,
  • Zhijia Hou,
  • Cuihong Liu,
  • Xue Jiang,
  • Ju Zhang,
  • Honglei Liu,
  • Dongmei Li

摘要

Purpose

To investigate the therapeutic effects of puerarin in reducing adipogenesis and controlling inflammation in primary orbital fibroblasts derived from patients with thyroid eye disease (TED), and to explore the potential underlying mechanisms.

Methods

After primary fibroblast culture and identification, the Cell Counting Kit-8 (CCK-8) was used to estimate the cytotoxic effects of puerarin. Wound-healing test was performed to assess the impact of puerarin on cellular migration. Adipogenic models were built with or without puerarin and inflammation model was built with the induction of IL-1β. Levels of IL-6, IL-8, CXCL-1, ADIPOQ, FABP4, and PPARγ were determined using quantitative real-time polymerase chain reaction (PCR). IL-6 and IL-8 in the cell supernatant were measured using enzyme-linked immunosorbent assay (ELISA). We performed network pharmacology and molecular docking to identify possible pathway and validated with Western blot.

Results

Puerarin significantly reduce the wound healing area and lipid area (p < 0.001, p = 0.004, p < 0.001 for 5µM, 10µM and 25µM, respectively) but no difference was found between the different puerarin groups. The levels of ADIPOQ, FABP4, and PPARγ were significantly decreased in the 5µM-puerarin treated group (p = 0.032, 0.041, 0.008, respectively), and the levels of IL-6 and IL-8 were significantly decreased in the puerarin-treated inflammation group (p < 0.01). PIK3CA and AKT 1 were identified as core targets, and the results were further supported by western blotting.

Conclusion

Puerarin has anti-adipogenic and anti-inflammatory effects on the fibroblasts of patients with TED. These effects may be mediated by the PI3K-AKT pathway. Puerarin may be a potential treatment option for TED.